In this video, Sven Borchmann, MD, University of Cologne, Cologne, Germany, discusses the importance of liquid biopsy as a diagnostic tool that may assist targeted therapy, and the challenges with using liquid biopsy assays in patients with lymphoma. Dr Borchmann also comments on the ongoing debate about whether these assays should be commercialized, and how to best implement these in clinical practice. This interview took place at the 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.